Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 46

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 46
---
.

Additionally, it is expected that Dr. Lennon, Mr. Giacobello and Mr. Ball will continue to serve as executive
officers of Aadi following the PIPE Financing and that all members of Aadi’s board of directors will continue to serve thereon following the PIPE Financing, and that such officers and directors will continue to receive cash and other
compensation (including benefits) for such services under applicable plans and arrangements which may be funded with proceeds from the PIPE Financing.

Aadi’s board of directors was aware of and considered those interests, among other matters, in reaching its decision to approve the PIPE Financing and
related matters, including the Subscription Agreement, Registration Rights Agreement and form of Pre-Funded Warrant, and recommend the approval of the PIPE Financing and related matters to Aadi stockholders.
These interests, among other factors, may have influenced the directors and executive officers of Aadi to support or approve the PIPE Financing.

Summary of the Equity Plan Increase Proposal (see page [●])

We are asking our stockholders to approve the amendment and restatement of our 2021 Plan (as amended and restated, the “Amended and Restated Plan”)
to (i) increase the number of shares available for future grant under the 2021 Plan from 2,000,284 shares to 8,300,284 shares and (ii) increase the 2021 Plan’s default annual automatic share reserve increase occurring on January 1 of each year
from 4% of outstanding shares on the last day of the immediately preceding fiscal year to 5% (the “Equity Plan Increase”).

Without the Equity
Plan Increase, we may not have sufficient shares available for grant under the 2021 Plan to make equity awards to our officers at market-based, competitive levels in 2025 and future years, to make promotion grants to our other employees at
market-based, competitive levels in 2025 and future years, to make annual grants to our other employees at market-based, competitive levels in 2025 and future years, or to make annual grants to our non-employee directors at market-based, competitive
levels in 2025 and future years until such time as we can obtain stockholder approval for an increase in shares for the 2021 Plan. If the Equity Plan Increase is not approved, we believe that we would be forced to rely on providing higher levels of
cash compensation or cash-settled awards for a portion of our incentive-based compensation in order to retain our most experienced and